Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07383311). This is a study registration, not published results. Lead sponsor: University Medicine Greifswald. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 76 participants (ESTIMATED). Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Subjective Cognitive Decline (SCD). Interventions: DIETARY_SUPPLEMENT: Spermidine Supplementation; DIETARY_SUPPLEMENT: Dietary Placebo. Primary outcome measures: Effects of spermidine supplementation on sleep quality as measured by electroencephalography (EEG) mean power spectra , baseline, 12-week follow-up; Effects of spermidine supplementation on sleep quality as measured by sleep spindle count assessed from EEG , baseline, 12-week follow-up; Effects of spermidine supplementation on sleep quality as measured by sleep spindle power assessed from EEG , baseline, 12-week follow-up; Effects of spermidine supplementation on sleep-related alertness as measured by computer-based task , baseline, 12-week follow-up; Effects of spermidine supplementation on sleep-related visual-spatial memory as measured by computer-based task , baseline, 12-week follow-up; Effects of spermidine supplementation on sleep-related verbal memory as measured by computer-based task , baseline, 12-week follow-up. Brief summary: This clinical trial investigates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), two populations at increased risk of future cognitive decline and dementia. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline. Spermidine is a naturally occurring polyamine found in foods such as wheat germ and soybeans. It induces autophagy, a cellular degradation and recycling process essential for neuronal maintenance and function. In animal studies, spermidine has been shown to improve memory performance, reduce neuroinflammation, and support mitochondrial health. Preliminary findings from human trials in individuals with SCD or MCI suggest potential cognitive benefits of spermidine, but results are not unequivocal, and the impact on sleep has not been systematically evaluated. In this randomized, double-blind, placebo-controlled trial, 76 participants aged 55 to 75 years with SCD or MCI will receive either spermidine (6 mg/day) or a placebo for 12 weeks. Sleep will be evaluated using overnight EEG in a controlled laboratory setting, focusing on measures such as slow-wave sleep and sleep spindle activity. Memory performance will be assessed before and after the intervention using standardized neuropsychological testing. Numerical skills will be tested at baseline only to compare SCD and MCI participants with healthy controls. Blood samples will be collected to quantify metabolic indicators, neurodegeneration-related biomarkers, and autophagy-associated proteins. A control group of 38 cognitively healthy individuals will undergo comparable sleep and cognitive assessments without receiving any supplementation. The primary objective of the study is to characterize the impact of spermidine on sleep-dependent memory consolidation and to identify associated biological changes relevant to aging and neurodegeneration. The results may inform the development of non-pharmacological strategies aimed at preserving cognitive function in individuals at risk for dementia.